ROIVRoivant Sciences Ltd. Common Shares
36.30USDMkt Cap: 26.22B $P/E: —3d ago
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully hu…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap26.22B $
Enterprise Value23.58B $
Revenue (TTM)7.53M $
Gross Profit6.97M $
Net Income (TTM)-299.77M $
Revenue/Share0.0110 USD
Last Price36.30 USD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees721
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-21.45
PEG—
EV/EBITDA-17.33
EV/Revenue3130.71
P/S3532.98
P/B6.29
EPS (TTM)-0.47
EPS (Forward)-1.72
52W Range
36.228% of range37.18
52W High37.18 USD
52W Low36.22 USD
Profitability
Gross Margin84.44%
Oper. Margin-25408.11%
EBITDA Margin0.00%
Profit Margin-3629.19%
ROE-6.62%
ROA-5.25%
Growth
Revenue Growth-33.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-750.35M $
CapEx (TTM)8.21M $
FCF Margin-14965.88%
FCF Yield-4.30%
Net Debt-3.73B $
Net Debt/EBITDA2.75
Balance Sheet
Debt/Equity0.02
Current Ratio16.72
Quick Ratio13.62
Book Value/Sh5.855 USD
Cash/Share5.319 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)41.82 USD
Upside (mean)+15.2%
Target Range37.00 USD – 50.00 USD
$37.00+15.2% to mean$50.00
# Analysts11
Ownership
Shares Out.722.32M
Float580.44M
Insiders21.45%
Institutions78.40%
Short Interest
Short Ratio7.5d
Short % Float6.42%
Short % Out.4.88%
Shares Short35.23M
Short (prev mo.)33.21M
Technical
SMA 5034.16 (+6.3%)
SMA 20027.58 (+31.6%)
Beta1.13
S&P 52W Chg21.00%
Avg Vol (30d)5.77M
Avg Vol (10d)6.43M
Technical Indicators
RSI (14)56.2
MACD0.7488
MACD Signal0.6704
MACD Hist.+0.0784
BB Upper38.00 USD
BB Middle35.38 USD
BB Lower32.77 USD
BB Width14.79%
ATR (14)1.212 USD
Vol Ratio (20d)1.03x